Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Acessos
Links relacionados
Similares em SciELO
Compartilhar
Gaceta mexicana de oncología
versão On-line ISSN 2565-005Xversão impressa ISSN 1665-9201
Resumo
O’CONNOR, Juan et al. Biomarkers and treatment characteristics in metastatic colorectal cancer RASwt patients in Latin America. Gac. mex. oncol. [online]. 2023, vol.22, n.1, pp.24-33. Epub 12-Jun-2023. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.22000074.
Objective:
To describe the use of biomarker testing and therapy options for RASwt patients with metastatic colorectal cancer (mCRC) in Argentina, Brazil, and Mexico during the 2017-2019 period.
Methods:
We conducted descriptive analysis using datasets from privately-owned research tools.
Results:
There was an increase in the use of tests performed for RAS, BRAF and MSI in all three countries. Between 2018 and 2019, RAS testing increased 15% in Argentina, 29% in Brazil and 3% in Mexico. MSI testing increased 18% in Argentina and 19% in Brazil but remained stable in Mexico at 12%. BRAF testing increased 45% in Brazil, in Argentina 46% and 29% in Mexico. Main first-line available options for m CRC were: Chemotherapy (CT), CT+ (EGFR inhibitor/anti-VEGF).
Conclusions:
Given the paucity of publicly available information on access to mCRC treatments in Latin America, findings from this private data-based study may be useful for decision-making processes among healthcare institutions.
Palavras-chave : Metastatic colorectal cancer; Biomarkers; RAS wild type; Target therapy; Latin America.